Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies

Abstract Objectives To determine rates of stroke or transient ischaemic attack (TIA) and all cause mortality in patients with a diagnosis of “resolved” atrial fibrillation compared to patients with unresolved atrial fibrillation and without atrial fibrillation. Design Two retrospective cohort studies. Setting General practices contributing to The Health Improvement Network, 1 January 2000 to 15 May 2016. Participants Adults aged 18 years or more with no previous stroke or TIA: 11 159 with resolved atrial fibrillation, 15 059 controls with atrial fibrillation, and 22 266 controls without atrial fibrillation. Main outcome measures Primary outcome was incidence of stroke or TIA. Secondary outcome was all cause mortality. Results Adjusted incidence rate ratios for stroke or TIA in patients with resolved atrial fibrillation were 0.76 (95% confidence interval 0.67 to 0.85, P<0.001) versus controls with atrial fibrillation and 1.63 (1.46 to 1.83, P<0.001) versus controls without atrial fibrillation. Adjusted incidence rate ratios for mortality in patients with resolved atrial fibrillation were 0.60 (0.56 to 0.65, P<0.001) versus controls with atrial fibrillation and 1.13 (1.06 to 1.21, P<0.001) versus controls without atrial fibrillation. When patients with resolved atrial fibrillation and documented recurrent atrial fibrillation were excluded the adjusted incidence rate ratio for stroke or TIA was 1.45 (1.26 to 1.67, P<0.001) versus controls without atrial fibrillation. Conclusion Patients with resolved atrial fibrillation remain at higher risk of stroke or TIA than patients without atrial fibrillation. The risk is increased even in those in whom recurrent atrial fibrillation is not documented. Guidelines should be updated to advocate continued use of anticoagulants in patients with resolved atrial fibrillation.

[1]  J. Healey,et al.  Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation , 2018 .

[2]  Josef Kautzner,et al.  Corrigendum to: 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2018, European heart journal.

[3]  T. Marshall,et al.  The role of contraindications in prescribing anticoagulants to patients with atrial fibrillation: a cross-sectional analysis of primary care data in the UK. , 2017, The British journal of general practice : the journal of the Royal College of General Practitioners.

[4]  D. Fitzmaurice,et al.  The treatment of paroxysmal atrial fibrillation in UK primary care , 2017, Heart.

[5]  G. Lip,et al.  Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care , 2017, Journal of the American Heart Association.

[6]  M. Link,et al.  Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48) , 2017, Circulation. Arrhythmia and electrophysiology.

[7]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[8]  L. Køber,et al.  Atrial fibrillation and risk of stroke: a nationwide cohort study. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[9]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[10]  E. Antman,et al.  Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) , 2016, Stroke.

[11]  L. Friberg,et al.  Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries. , 2016, European heart journal.

[12]  P. Noseworthy,et al.  Risk of stroke after catheter ablation versus cardioversion for atrial fibrillation: A propensity-matched study of 24,244 patients. , 2015, Heart rhythm.

[13]  Á. Avezum,et al.  Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. , 2015, European heart journal.

[14]  T. Chao,et al.  Can oral anticoagulants be stopped safely after a successful atrial fibrillation ablation? , 2015, Journal of thoracic disease.

[15]  M. Cowie.  National Institute for Health and Care Excellence. , 2015, European heart journal.

[16]  A. Jaffe,et al.  A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2015 .

[17]  M. Ezekowitz,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. , 2014, Circulation.

[18]  J. Healey,et al.  2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. , 2014, The Canadian journal of cardiology.

[19]  I. White,et al.  Smoker, ex-smoker or non-smoker? The validity of routinely recorded smoking status in UK primary care: a cross-sectional study , 2014, BMJ Open.

[20]  Lennart Bergfeldt,et al.  Atrial Fibrillation, Stroke Risk, and Warfarin Therapy Revisited: A Population-Based Study , 2013, Stroke.

[21]  H. May,et al.  Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. , 2013, Heart rhythm.

[22]  G. Breithardt,et al.  Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. , 2013, Journal of the American College of Cardiology.

[23]  C. Gale,et al.  The use of anticoagulants in the management of atrial fibrillation among general practices in England , 2013, Heart.

[24]  K. Kuck,et al.  Catheter ablation of long-standing persistent atrial fibrillation: 5-year outcomes of the Hamburg Sequential Ablation Strategy. , 2012, Journal of the American College of Cardiology.

[25]  Gerhard Hindricks,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[26]  T. Chao,et al.  Clinical Outcome of Catheter Ablation in Patients With Nonparoxysmal Atrial Fibrillation: Results of 3-Year Follow-Up , 2012, Circulation. Arrhythmia and electrophysiology.

[27]  Silvia G Priori,et al.  2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.

[28]  A. Maguire,et al.  The importance of defining periods of complete mortality reporting for research using automated data from primary care , 2009, Pharmacoepidemiology and drug safety.

[29]  M. Aguilar,et al.  Oral Anticoagulants Versus Antiplatelet Therapy for Preventing Stroke in Patients With Nonvalvular Atrial Fibrillation and No History of Stroke or Transient Ischemic Attacks , 2008 .

[30]  D. Cook,et al.  Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care , 2005, Heart.

[31]  M. Aguilar,et al.  Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. , 2005, The Cochrane database of systematic reviews.

[32]  A. Dhar,et al.  National Institute for Health and Clinical Excellence , 2005 .

[33]  J. Mounsey,et al.  Antiarrhythmic drug therapy of atrial fibrillation. , 2004, Cardiology clinics.

[34]  A. Connor,et al.  The way I see it: House officers need formal career development , 2002 .

[35]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[36]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[37]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.